Selective serotonin reuptake inhibitors

Last updated: September 01, 2023

Selective serotonin reuptake inhibitors

Watch later

Watch later

Introduction to pharmacology
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Drug administration and dosing regimens
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
ACE inhibitors, ARBs and direct renin inhibitors
Miscellaneous lipid-lowering medications
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
cGMP mediated smooth muscle vasodilators
Calcium channel blockers
Positive inotropic medications
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Adrenergic antagonists: Presynaptic
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Hyperthyroidism medications
Hypothyroidism medications
Mineralocorticoids and mineralocorticoid antagonists
Adrenal hormone synthesis inhibitors
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Anti-tumor antibiotics
Microtubule inhibitors
Platinum containing medications
Topoisomerase inhibitors
Ribonucleotide reductase inhibitors
Glucocorticoids
Non-corticosteroid immunosuppressants and immunotherapies
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Miscellaneous protein synthesis inhibitors
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Integrase and entry inhibitors
Protease inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Hepatitis medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anti-mite and louse medications
Anthelmintic medications
Antimalarials
Acetaminophen (Paracetamol)
Antigout medications
Non-steroidal anti-inflammatory drugs
Osteoporosis medications
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
General anesthetics
Local anesthetics
Migraine medications
Nonbenzodiazepine anticonvulsants
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid antagonists
Sympathomimetics: Direct agonists
Tricyclic antidepressants
Atypical antidepressants
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Monoamine oxidase inhibitors
Psychomotor stimulants
Typical antipsychotics
Atypical antipsychotics
Lithium
Loop diuretics
Carbonic anhydrase inhibitors
Osmotic diuretics
Potassium sparing diuretics
Thiazide and thiazide-like diuretics
Androgens and antiandrogens
Estrogens and antiestrogens
Progestins and antiprogestins
Uterine stimulants and relaxants
Aromatase inhibitors
PDE5 inhibitors
Antihistamines for allergies
Pulmonary corticosteroids and mast cell inhibitors
Bronchodilators: Leukotriene antagonists and methylxanthines
Bronchodilators: Beta 2-agonists and muscarinic antagonists

Transcript

Watch video only

Selective Serotonin Reuptake inhibitors, or SSRIs, are mainly used to treat major depressive disorder. This disorder causes a persistent feeling of sadness and loss of interest in everyday activities. Even though the exact cause of depression is still unknown, there's some evidence that suggests it’s related to low levels of neurotransmitters like serotonin, norepinephrine, and dopamine. Selective serotonin reuptake inhibitors work by increasing the levels of serotonin to alleviate the symptoms of depression.

Now, serotonin is a neurotransmitter that helps regulate mood, emotions and feeding behavior. Presynaptic serotonergic neurons use the amino acid tryptophan to synthesize serotonin, which is also called 5-hydroxytryptamine, or 5-HT. Once synthesized, serotonin is stored in small vesicles within the presynaptic neuron. When an action potential reaches the presynaptic membrane, the vesicles fuse with the membrane and release the serotonin into the synaptic cleft. The serotonin drift around until they bind to 5HT2 receptors on the postsynaptic neuron, and cause it to fire off its own action potential. As long as there’s a high enough concentration of serotonin in the synaptic cleft, the postsynaptic neuron will continue to fire. On the presynaptic neuron, there are serotonin reuptake transporters or SERTs. This protein functions like a little trap door on the cell membrane; when a sodium, a chloride and a serotonin binds to the surface of this protein on the extracellular side, it flips over and sends the serotonin and the ions into the cell. When a potassium ion binds to the protein on the intracellular side, the trapdoor resets again, so more serotonin can attach. This way, serotonin is taken back into the presynaptic neuron, its concentration in the synaptic cleft decreases, and the postsynaptic neuron stops firing.

Now, in conditions such as major depressive disorder, where there’s a low serotonin level, selective serotonin reuptake inhibitors are the first-line therapy due to their milder side effects. Common medications in this class include escitalopram, fluoxetine, fluvoxamine, sertraline, paroxetine, and citalopram. They bind to serotonin reuptake transporters and inhibits them, which increases the serotonin level within the synaptic cleft. It's important to note that these medications are slow-acting because it takes time for serotonin to accumulate within the synaptic cleft. Because of this, it usually takes 4-6 weeks before improvements can be seen. Other conditions that can be treated with SSRIs include chronic anxiety, post traumatic stress disorder, or PTSD, obsessive-compulsive disorder, or OCD, and eating disorders like bulimia.

Common side effects of SSRIs include anxiety, insomnia or drowsiness, GI distress, sexual dysfunction, and syndrome of inappropriate antidiuretic hormone or SIADH. The most dangerous, however, are suicidal ideations, especially in individuals under 25, and serotonin syndrome. Serotonin syndrome is a life threatening condition caused by serotonin accumulation which causes overstimulation of the nervous system. This syndrome is characterized by skin flushing, hyperthermia, agitation, muscle rigidity, seizure, and coma. It usually occurs in individuals treated with a combination of SSRIs and other antidepressants that increase serotonin level, such as monoamine oxidase inhibitors.

Key Takeaways

Selective serotonin reuptake inhibitors, or SSRIs, are a class of antidepressant medications commonly used in the treatment of major depressive disorders, post-traumatic stress disorder, obsessive-compulsive disorder, chronic anxiety disorders, and eating disorders like bulimia. SSRIs work by preventing serotonin reuptake from the synaptic cleft, thus increasing the amount of serotonin binding to 5HT2 receptors. SSRIs have a few dangerous side effects like increased risk of suicide and life-threatening serotonin syndrome.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Neuroleptic malignant syndrome and serotonin syndrome" Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part II (2018)
  5. "Mechanism of action of antidepressant medications" J Clin Psychiatry (1999)
  6. "Selective Serotonin Reuptake Inhibitors" Antidepressants (2018)